Mark Morgan

Dante Labs, Inc. operates as a genetic testing laboratory. The company was founded by Andrea Riposati and Mattia Capulli in 2016 and is headquartered in New York, NY.

Dante Labs Srl provides genetic testing laboratory services. The firm offers sequencing-based genetic tests, including hereditary cancer and cardiovascular disease risk assessment tests directly to consumers in Europe. It has offices in Italy and New York. The company was founded by Mattia Capulli and Andrea Riposati in 2016 and is headquartered in Pizzoli, Italy.

ArcherDX LLC is a genomic analysis company, which develops software solutions for investigating cancer treatment. Its products include VariantPlex, FusionPlex, LiquidPlex, reveal ctDNA, Immunoverse, custom assays, and archer analysis. The company was founded by Jason W. Myers, A. John Iafrate, and Long Phi Le on January 1, 2013 and is headquartered in Boulder, CO.

Arrogene, Inc. commercializes a cancer treatment technology and a proprietary molecular delivery platform. Its technology delivers peptide, protein and oligonucleotide therapeutics across the blood-brain barrier to cancer cells to prevent tumor growth or for imaging. The company was founded by Julia Ljubimova, Alexander Ljubimova, Keith Black and Eggehard Holler in 2006 and is headquartered in Los Angeles, CA.

Foresight Diagnostics, Inc. is a privately held cancer diagnostics company based in Aurora, CO. The company has developed a liquid biopsy testing platform for the measurement of minimal residual disease (MRD) that is significantly more sensitive than existing tests, with a detection limit below 0.0001% or one part-per-million. This improved sensitivity provides actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with a variety of cancers. The company's experts specialize in liquid biopsy and cancer genomics, developing an MRD assay centered on the detection of ctdna via phased variant sequencing. The company uses phased-seq® liquid biopsy technology for cancer relapse surveillance by monitoring cfdna/ctdna in the blood of lymphoma and lung cancer patients. The company was founded by Maximilian Diehn, Ash Alizadeh, Jake Chabon, and David Kurtz, with Jake Chabon serving as the CEO since incorporation.